Pathophysiology and Treatment of Pulmonary Hypertension

肺动脉高压的病理生理学和治疗

• 批准号: 6458821
• 负责人: MARC R MOON
• 金额: $ 26.82万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-04-01 至 2005-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6458821
• 关键词: atrium; calcium channel blockers; cardiac output; cardiovascular disorder therapy; chronic disease /disorder; dogs; drug adverse effect; heart contraction; heart failure; heart function; heart surgery; heart ventricle; nonhuman therapy evaluation; pathologic process; prostacyclins; pulmonary artery; pulmonary hypertension; respiratory disease /disorder therapy; vascular resistance; vasodilation

Chronic pulmonary hypertension (CPH) is a devastating disease - its progression is relentless, culminating in right heart failure (RHF) and death in the majority of patients. Unfortunately, our knowledge of the pathophysiologic sequelae that portend cardiac failure with CPH remains grossly inadequate to direct patient care for this increasingly important disease process. Furthermore, the mechanisms of action of common medical and surgical treatment options remain unknown, and the individual patient's response to therapy is unpredictable. Using a standard experimental model of CPH in animals, RHF will be created and studied with two novel techniques: 1.) Right atrial (RA) volume clamping, and 2.) Feedback-loop controlled pulmonary artery (PA) occlusion. The RA volume-clamping technique will permit, for the first time, isolation of the mechanics of RA function, including its contribution to cardiac output and compensatory role in CPH. In addition, feedback-loop controlled PA occlusion will permit differentiation of the indirect vasodilatory effects from the direct myocardial effects of popular therapeutic regimens on right heart mechanics. A series of experiments will assess the impact of common medical therapies and new, as of yet unproven, surgical therapies on right heart function and global cardiac performance. The proposed studies will address the following specific aims: l.) Define the pathophysiologic sequelae of CPH that produce RHF; 2.) Determine the balance between afterload reduction, changes in diastolic relaxation and compliance, and contractile inhibition with common, but poorly understood medical therapeutic agents; and 3.) Determine the physiologic consequences of graded atrial septostomy on right heart function and total cardiac output in subjects with varying degrees of CPH. The long-range goals of this project are to understand the physiologic sequelae of this crippling disease, guide appropriate medical and surgical therapy, and develop, new treatment strategies that will improve outcome for patients with CPH.

慢性肺动脉高压(CPH)是一种破坏性的疾病，它的发展是无情的，最终导致右心衰竭(RHF)和大多数患者的死亡。不幸的是，我们对CPH心力衰竭的病理生理后遗症的了解仍然严重不足，不足以指导患者对这一日益重要的疾病过程的护理。此外，常见的内科和外科治疗方案的作用机制仍不清楚，个别患者对治疗的反应也是不可预测的。使用动物CPH的标准实验模型，将用两种新技术创建和研究RHF：1)(2)右心房(RA)容量阻断；反馈环控制的肺动脉阻断。RA容量钳制技术将首次允许分离RA功能的机制，包括它对心输出量的贡献和CPH中的代偿作用。此外，反馈环控制的PA阻断将允许区分右心力学常用治疗方案的间接血管扩张效应和直接心肌效应。一系列实验将评估普通医学疗法和尚未得到证实的新外科疗法对右心功能和全球心脏功能的影响。拟议的研究将涉及以下具体目标：L。)明确CPH引起RHF的病理生理后遗症；确定后负荷减少、舒张期松弛和顺应性的变化以及使用常见但知之甚少的药物抑制收缩之间的平衡；探讨不同程度CPH患者分级房间隔造口术对右心功能和心输出量的生理影响。该项目的长期目标是了解这种致残性疾病的生理后遗症，指导适当的内科和外科治疗，并开发新的治疗策略，以改善CPH患者的预后。